XML 41 R27.htm IDEA: XBRL DOCUMENT v3.7.0.1
Balance Sheet Account Detail (Tables)
 3 Months Ended
Mar. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Cash And Cash Equivalent Marketable Securities Unrealized Gain Table
The following is a summary of our presented “cash and cash equivalents” and “marketable securities”:
 
 
 
 
 
 
 
 
 
 
 
Marketable Securities
 
Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Estimated
Fair
Value
 
Cash and Cash
Equivalents
 
Current
 
Long
Term
March 31, 2017
 
 
 
 
 
 
 
 
 
 
 
 
 
Bank deposits
$
12,757

 
$
—

 
$
—

 
$
12,757

 
$
12,757

 
$
—

 
$
—

Money market funds
124,439

 
—

 
—

 
124,439

 
124,439

 
—

 
—

Bank certificates of deposits
247

 
—

 
—

 
247

 
—

 
247

 
—

Total cash and cash equivalents and marketable securities
$
137,443

 
$
—

 
$
—

 
$
137,443

 
$
137,196

 
$
247

 
$
—

December 31, 2016
 
 
 
 
 
 
 
 
 
 
 
 
 
Bank deposits
$
23,915

 
$
—

 
$
—

 
$
23,915

 
$
23,915

 
$
—

 
$
—

Money market funds
128,563

 
—

 
—

 
128,563

 
128,563

 
—

 
—

Bank certificates of deposits
5,991

 
—

 
—

 
5,991

 
5,744

 
247

 
—

Total cash and cash equivalents and marketable securities
$
158,469

 
$
—

 
$
—

 
$
158,469

 
$
158,222

 
$
247

 
$
—
Schedule of Property and Equipment Net of Accumulated Depreciation
“Property and equipment, net of accumulated depreciation” consist of the following: 
 
March 31, 2017
 
December 31, 2016
Computer hardware and software
$
2,684

 
$
2,550

Laboratory equipment
622

 
622

Office furniture
217

 
211

Leasehold improvements
2,912

 
2,912

Property and equipment, at cost
6,435

 
6,295

(Less): Accumulated depreciation
(5,942
)
 
(5,846
)
Property and equipment, net of accumulated depreciation
$
493

 
$
449
Components of Inventories
“Inventories” consist of the following: 
 
March 31, 2017
 
December 31, 2016
Raw materials
$
2,028

 
$
2,991

Work-in-process
10,690

 
7,838

Finished goods
1,620

 
2,305

(Less:) Non-current portion of inventories included within "other assets" *
(3,950
)
 
(4,419
)
Inventories
$
10,388

 
$
8,715


* The "non-current" portion of inventories is presented within "other assets" in the accompanying Condensed Consolidated Balance Sheets at March 31, 2017 and December 31, 2016, respectively. This value of $4.0 million at March 31, 2017 represents product that we expect to sell beyond March 31, 2018.
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure
“Prepaid expenses and other assets” consist of the following:
 
March 31, 2017
 
December 31, 2016
Prepaid insurance
$
557

 
$
721

Inventory other
1,501

 
1,458

Other miscellaneous prepaid operating expenses
1,668

 
1,751

Prepaid expenses and other assets
$
3,726

 
$
3,930
Schedule of Other Receivables
“Other receivables” consist of the following:
 
March 31, 2017
 
December 31, 2016
Income tax receivable
$
—

 
$
1,388

Insurance receivable
759

 
500

CASI note - short term*
1,512

 
—

Receivable for contracted sales and marketing services (Note 13)
1,590

 
1,831

Reimbursements due from development partners for incurred research and development expenses
1,373

 
1,796

Other miscellaneous receivables**
714

 
239

Other receivables
$
5,948

 
$
5,754


* This full balance was prospectively reclassified beginning March 31, 2017 to "other receivables" (presented within current assets on the accompanying Condensed Consolidated Balance Sheets) from "other assets" (presented within non-current assets) due to this note's maturity date of March 17, 2018 (i.e., within 12 months of March 31, 2017) - see Note 10.
** As of March 31, 2017 the balance of "other miscellaneous receivables" is inclusive of $0.4 million of Medicaid rebate credits to be applied against future invoices for each respective state program.
Components of Intangible Assets Net of Accumulated Amortization
“Intangible assets, net of accumulated amortization and impairment charges” consist of the following: 
 
 
 
March 31, 2017
 
Historical
Cost
 
Accumulated
Amortization
 
Foreign
Currency
Translation
 
Impairment
 
Net Amount
 
Full
Amortization
Period
(months)
 
Remaining
Amortization
Period
(months)
MARQIBO IPR&D (NHL and other novel indications)
$
17,600

 
$
—

 
$
—

 
$
—

 
$
17,600

 
n/a
 
n/a
EVOMELA distribution rights (1)
7,700

 
(592
)
 
—

 
—

 
7,108

 
156
 
144
BELEODAQ distribution rights
25,000

 
(5,156
)
 
—

 
—

 
19,844

 
160
 
127
MARQIBO distribution rights
26,900

 
(13,943
)
 
—

 
—

 
12,957

 
81
 
36
FOLOTYN distribution rights (2)
118,400

 
(44,305
)
 
—

 
—

 
74,095

 
152
 
68
ZEVALIN distribution rights – U.S.
41,900

 
(34,951
)
 
—

 
—

 
6,949

 
123
 
24
ZEVALIN distribution rights – Ex-U.S.
23,490

 
(14,241
)
 
(4,747
)
 
—

 
4,502

 
96
 
36
FUSILEV distribution rights (3)
16,778

 
(9,618
)
 
—

 
(7,160
)
 
—

 
56
 
0
FOLOTYN out-license (4)
27,900

 
(12,513
)
 
—

 
(1,023
)
 
14,364

 
110
 
64
Total intangible assets
$
305,668

 
$
(135,319
)
 
$
(4,747
)
 
$
(8,183
)
 
$
157,419

 
 
 
 
 
(1)
The FDA approval of EVOMELA in March 2016 triggered a $6 million payment due to CyDex Pharmaceuticals, Inc. (a wholly-owned subsidiary of Ligand Pharmaceuticals Incorporated ("Ligand")). This event also resulted in a reclassification of our $7.7 million "EVOMELA IPR&D" to "EVOMELA distribution rights" due to our ability to begin its commercialization with this FDA approval. Amortization commenced on April 1, 2016, in accordance with our capitalization policy for intangible assets.

(2)
Beginning June 2016, we adjusted the amortization period of our FOLOTYN distribution rights to November 2022 from March 2025, representing the period through which we expect to have patent protection from generic competition (see Note 16(g)).

(3)
On February 20, 2015, the U.S. District Court for the District of Nevada found the patent covering FUSILEV to be invalid, which was upheld on appeal. On April 24, 2015, Sandoz began to commercialize a generic version of FUSILEV. This represented a “triggering event” under applicable GAAP in evaluating the value of our FUSILEV distribution rights as of March 31, 2015, resulting in a $7.2 million impairment charge (non-cash) in the first quarter of 2015. We accelerated amortization expense recognition in 2015 for the then remaining net book value of FUSILEV distribution rights.

(4)
On May 29, 2013, we amended our FOLOTYN collaboration agreement with Mundipharma International Corporation Limited ("Mundipharma"). As a result of the amendment, Europe and Turkey were excluded from Mundipharma’s commercialization territory, and their royalty rates and milestone payments to us were modified. This constituted a change under which we originally valued the FOLOTYN out-license as part of business combination accounting, resulting in an impairment charge (non-cash) of $1.0 million in the second quarter of 2013.

 
 
 
December 31, 2016

Historical
Cost
 
Accumulated
Amortization
 
Foreign
Currency
Translation
 
Impairment
 
Net Amount
MARQIBO IPR&D (NHL and other novel indications)
$
17,600

 
$
—

 
$
—

 
$
—

 
$
17,600

EVOMELA distribution rights
7,700

 
(444
)
 
—

 
—

 
7,256

BELEODAQ distribution rights
25,000

 
(4,688
)
 
—

 
—

 
20,312

MARQIBO distribution rights
26,900

 
(12,863
)
 
—

 
—

 
14,037

FOLOTYN distribution rights
118,400

 
(41,036
)
 
—

 
—

 
77,364

ZEVALIN distribution rights – U.S.
41,900

 
(34,083
)
 
—

 
—

 
7,817

ZEVALIN distribution rights – Ex-U.S.
23,490

 
(13,649
)
 
(5,038
)
 
—

 
4,803

FUSILEV distribution rights
16,778

 
(9,618
)
 
—

 
(7,160
)
 
—

FOLOTYN out-license
27,900

 
(11,832
)
 
—

 
(1,023
)
 
15,045

Total intangible assets
$
305,668

 
$
(128,213
)
 
$
(5,038
)
 
$
(8,183
)
 
$
164,234
Estimated Intangible Asset Amortization Expense
Estimated intangible asset amortization expense for the remainder of 2017 and the five succeeding fiscal years and thereafter is as follows:

Years Ending December 31,
 
Remainder of 2017
$
20,670

2018
27,560

2019
24,955

2020
19,721

2021
18,266

2022
15,882

2023 and thereafter
12,765

 
$
139,819
Schedule of Goodwill
“Goodwill” is comprised of the following:
 
March 31, 2017
 
December 31, 2016
Acquisition of Talon (MARQIBO rights)
$
10,526

 
$
10,526

Acquisition of ZEVALIN Ex-U.S. distribution rights
2,525

 
2,525

Acquisition of Allos (FOLOTYN rights)
5,346

 
5,346

Foreign currency exchange translation effects
(480
)
 
(511
)
Goodwill
$
17,917

 
$
17,886
Summary of Other Assets
“Other assets” are comprised of the following: 
 
March 31, 2017
 
December 31, 2016
Equity securities (see Note 10)*
$
14,241

 
$
11,533

CASI note - long term (see Note 10)**
—

 
1,510

Research & development supplies and other
230

 
224

Executive officer life insurance – cash surrender value
12,263

 
11,863

Inventories - non-current portion
3,950

 
4,419

Other assets
$
30,684

 
$
29,549


* These equity securities were excluded from “marketable securities” (see Note 3(a)) due to our intent to hold these securities for at least one year beyond March 31, 2017 (see Note 10). The “unrealized gain on available-for-sale securities" within the Condensed Consolidated Statements of Comprehensive Loss, totaled $1.8 million, net of income tax, for the three months ended March 31, 2017.

** This full balance was prospectively reclassified beginning March 31, 2017 to "other receivables" (presented within current assets in the accompanying Condensed Consolidated Balance Sheets) from "other assets" (presented within non-current assets) due to this note's maturity date of March 17, 2018 (i.e., within 12 months of March 31, 2017) - see Note 10.
Schedule of Accounts Payable and Other Accrued Liabilities
“Accounts payable and other accrued liabilities” are comprised of the following:
 
March 31, 2017
 
December 31, 2016
Trade accounts payable and other accrued liabilities
$
27,719

 
$
30,488

Accrued rebates
8,910

 
8,350

Accrued product royalty
3,519

 
4,723

Allowance for returns
2,553

 
2,309

Accrued data and distribution fees
2,611

 
4,222

Accrued GPO administrative fees
384

 
384

Accrued inventory management fee
876

 
540

Allowance for chargebacks
1,656

 
1,467

Accounts payable and other accrued liabilities
$
48,228

 
$
52,483
Schedule of Amounts Presented in Accounts Payable and Other Accrued Liabilities
Amounts presented within “accounts payable and other accrued liabilities” in the accompanying Condensed Consolidated Balance Sheets for GTN estimates (see Note 2(i)) were as follows:

Rebates and
Chargebacks
 
Data and
Distribution,
GPO Fees, and
Inventory
Management
Fees
 
Returns
Balance as of December 31, 2015
$
20,167

 
$
3,386

 
$
1,394

Add: provisions
98,317

 
14,979

 
2,123

(Less): credits or actual allowances
(108,667
)
 
(13,219
)
 
(1,208
)
Balance as of December 31, 2016
9,817

 
5,146

 
2,309

Add: provisions
27,385

 
4,466

 
310

(Less): credits or actual allowances
(26,636
)
 
(5,741
)
 
(66
)
Balance as of March 31, 2017
$
10,566

 
$
3,871

 
$
2,553
Deferred Revenue, by Arrangement, Disclosure
Deferred revenue (current and non-current) is comprised of the following:

March 31, 2017
 
December 31, 2016
ZEVALIN out-license deferred revenue in Asia Territory (see Note 11)
$
640

 
$
1,255

EVOMELA deferred revenue*
2,235

 
1,887

ZEVALIN out-license in India territory (see Note 16(b)(iii))
363

 
369

Deferred revenue
$
3,238

 
$
3,511

* We commercialized EVOMELA beginning in April 2016, and have deferred revenue recognition (see Note 2(i)(a)) for any product shipped to our distributors, but not ordered and received by end-users as of March 31, 2017 and December 31, 2016. This deferral is a result of our present inability to estimate future customer returns and rebate levels for this recently launched product
Summary of Other Long-Term Liabilities
"Other long-term liabilities" are comprised of the following:
 
March 31, 2017
 
December 31, 2016
Accrued executive deferred compensation
$
8,942

 
$
8,352

Deferred rent (non-current portion)
143

 
167

Clinical study holdback costs, non-current
51

 
47

Other tax liabilities
738

 
738

Royalty liability
—

 
300

Other long-term liabilities
$
9,874

 
$
9,604